Clinical Trial Update: VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

View source ↗

Summary

A post-authorization study (VALEO) update evaluating the safety and effectiveness of bortezomib in the Netherlands has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Neoplasms
• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Janssen-Cilag B.V. | Conditions: Multiple Myeloma, Hematological Neoplasms | Status: COMPLETED